Anatara Life Sciences (ASX: ANR) swiftly progresses its clinical trials

3 min read | April 01, 2022 07:25 PM AEDT | By Aditi Sarkar

Google News:

Anatara Life Sciences (ASX: ANR) swiftly progresses its clinical trials — Image source: © Sdecoret| Megapixl.com

Recruitment is ongoing for two human trials with ethical approval

Trial sites

Anticipated results

GaRP in Irritable Bowel Syndrome – diarrhoea subtype (IBS-D)

Paratus Clinical Research, CSIRO Nutrition and Health Research Clinic

Interim – August 2022

Final – January 2023

3FDC in psychological functioning (anxiety, depression, stress)

CSIRO Nutrition and Health Research Clinic

Final – Late 2022

There is a high instance of digestive disorders on a worldwide basis. This requires relief from both symptoms and the disease process, including irritable bowel syndrome (IBS). The gut-“brain axis” and the impact of the microbiome are also gaining traction. The GaRP complementary medicine offers a significant market opportunity to address these concerns while improving people's quality of life.

Do read: Recce Pharmaceuticals (ASX:RCE) shares encouraging trial data for next-gen antibiotic

irritable bowel syndrome

Image source: © Nupittu | Megapixl.com

Gastrointestinal ReProgramming (GaRP)

GaRP is Anatara's proof-based complementary medicine. It contains novel formulations of Bromelain (enzyme extracted from pineapple stems) and other synergistic GRAS (Generally Recognised as Safe) constituents. The combination and coating of these GaRP components have a favourable effect on the physiology of the gastrointestinal (GI) lining. It has a favourable impact on the microbiome (homeostasis & metabolites) and it enables absorption of valuable components in affected areas of the GI tract.

" 3FDC" is the company's working reference to specific components from the overall GaRP product. Components of 3FDC are generally coated for targeted release ahead of the small intestine to permit delivery and influence in the large intestine. It is expected to have direct and indirect impacts, including helping in the homeostasis of a healthy microbiome.

The delivery of these components and the impact on the microbiome are thought to be good for the gut-brain balance. Therefore, 3FDC components are selected to discover their impact on depression, anxiety and stress symptom in normal healthy individuals.

The company is looking forward to continuing these human clinical trials while progressing in commercialising both human and animal gut health portfolios.

Also read: Polynovo (ASX:PNV) shows uptrend after shedding 58% in a year

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.